APOA2–265 T>C Polymorphism as A Genetic Marker Associated with Lipid Profiles and Cardiovascular Risk in A Healthy Indonesian Population
Abstract
BACKGROUND: Apolipoprotein A (APOA)2–265 T>C polymorphism significantly affects lipid metabolism and body composition, as well as plays a key role in cardiovascular diseases (CVD) and metabolic syndrome. In this study, association between the APOA2 polymorphism, lipid profiles, body composition, and cardiovascular disease (CVD) risk in a healthy Indonesian population was investigated. Although similar studies have been conducted in other populations, this study addresses the urgent need to understand genetic factors influencing lipid profiles in Southeast and East Asia, where hypercholesterolemia rate keep rising, particularly in Indonesia.
METHODS: A cross-sectional study involving 84 healthy participants was performed. Genotyping for the APOA2–265 T>C polymorphism was conducted using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Plasma levels of APOA2 and APOB100 were measured with enzyme-linked immunosorbent assay (ELISA), and APOB100/APOA2 ratio was calculated to assess CVD risk. Lipid profiles were evaluated with enzymatic methods, and body fat percentage was measured using calipers.
RESULTS: CT/CC genotypes showed significantly lower plasma APOA2 levels compared to the TT genotype (p=0.0215). APOB100/APOA2 ratio was significantly higher in CT/CC genotypes (p=0.0020) and remained significant after Bonferroni correction. No significant differences were found in lipid profiles and body fat percentages between genotypes after correction, although trends suggested higher cholesterol and low-density lipoprotein (LDL) levels in TT genotypes and higher median body fat percentages in CC/CT genotypes.
CONCLUSION: APOA2–265 T>C polymorphism is linked to changes in lipid profiles and body composition, potentially raising CVD risk in CT/CC genotypes. However, limited sample size and modest effect sizes suggest that the practical use of APOA2 genotyping for risk assessment might require further investigation.
KEYWORDS: APOA2 polymorphism, APOB100, hypercholesterolemia, cardiovascular disease, lipid profile, body fat percentage
Full Text:
PDFReferences
Mørland JG, Magnus P, Vollset SE, Leon DA, Selmer R, Tverdal A. Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345,000 men and women aged 20-79 years. Int J Epidemiol. 2023; 52(4): 1257-67, CrossRef.
SCORE2 working group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: New models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42(25): 2439-54, CrossRef.
Razo C, Johnson CO, Shakil SS, Roth GA. Abstract MP20: Global burden of elevated low-density lipoprotein cholesterol, 1990-2020: findings from the Global Burden of Disease Study 2020. Circulation. 2022; 145(Suppl 1): AMP20-AMP20, CrossRef.
Chang T, Streja E, Ko G, Naderi N, Rhee CM, Kashyap M, et al. Inverse association between serum non-high‐density lipoprotein cholesterol levels and mortality in patients undergoing incident hemodialysis. J Am Heart Assoc. 2018; 7: e009096, CrossRef.
Al-Zahrani J, Shubair M, Al-Ghamdi S, Alrasheed AA, Alduraywish A, Alreshidi F, et al. The prevalence of hypercholesterolemia and associated risk factors in Al-Kharj population, Saudi Arabia: A cross-sectional survey. BMC Cardiovasc Disord. 2021; 21: 22, CrossRef.
World Heart Federation. World Heart Report 2023: Confronting the World's Number One Killer. Geneva: World Heart Federation; 2023, article.
Ministry of Health, Republic of Indonesia. Laporan Nasional RISKESDAS 2018. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan; 2018, article.
Hisamatsu T. Apolipoprotein A2 isoforms: New insight into the risk of myocardial infarction. J Atheroscler Thromb. 2021; 28(5): 469-70, CrossRef.
Chlebus K, Zdrojewski T, Gruchała M, Gałąska R, Pajkowski M, Romanowska-Kocejko M, et al. Cardiovascular risk factor profiles in familial hypercholesterolemia patients with and without genetic mutation compared to a nationally representative sample of adults in a high-risk European country. Am Heart J. 2019; 218: 32-45, CrossRef.
Chan DC, Pang J, Hooper AJ, Burnett JR, Bell DA, Bates TR, et al. Elevated lipoprotein(a), hypertension, and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia. Int J Cardiol. 2015; 201: 633-8, CrossRef.
Keramat L, Sadrzadeh-Yeganeh H, Sotoudeh G, Zamani E, Eshraghian M, Mansoori A, et al. Apolipoprotein A2− 265 T> C polymorphism interacts with dietary fatty acids intake to modulate inflammation in type 2 diabetes mellitus patients. Nutrition. 2017; 37: 86-91, CrossRef.
Al-Bustan SA, Alnaqeeb MA, Annice BG, Ebrahim GA, Refai TM. Genetic association of APOB polymorphisms with variation in serum lipid profile among the Kuwait population. Lipids Health Dis. 2014; 13: 157, CrossRef.
Hamuaty RB, Sukmawati IR, Sandra F. Relationship between sRAGE and hsCRP as markers of cadiovascular disease risk factors in diabetic and non-diabetic men with central obesity. Mol Cell Biomed Sci. 2017; 1(2): 70-4, CrossRef.
Kopin L, Lowenstein C. In the Clinic® dyslipidemia. Ann Intern Med. 2017; 167(11): ITC81-95, CrossRef.
Meiliana A, Dewi NM, Wijaya A. The high density lipoprotein cholesterol hypothesis revisited. Indones Biomed J. 2018; 10(2): 84-103, CrossRef.
Sargowo D, Handayani O. Association between cardiovascular risk and elevated triglycerides. Indones Biomed J. 2017; 9(1): 17-22, CrossRef.
Zhu L, Lu Z, Zhu L, Ouyang X, Yang Y, He W, et al. Lipoprotein ratios are better than conventional lipid parameters in predicting coronary heart disease in Chinese Han people. Kardiol Pol (Polish Hear Journal). 2015; 73(10): 931-8, CrossRef.
Aditama L, Rahmawati D, Parfati N, Pratidina A. CVD risk and barriers to physical activity. Indones Biomed J. 2015; 7(1): 43-8, CrossRef.
Zaki ME, Amr KS, Abdel-Hamid M. APOA2 polymorphism in relation to obesity and lipid metabolism. Cholesterol. 2013; 2013: 289481, CrossRef.
Paquette M, Chong M, Thériault S, Dufour R, Paré G, Baass A. Polygenic risk score predicts prevalence of cardiovascular disease in patients with familial hypercholesterolemia. J Clin Lipidol. 2017; 11(3): 725-32.e5, CrossRef.
Akioyamen LE, Genest J, Chu A, Inibhunu H, Ko DT, Tu JV. Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis. J Clin Lipidol. 2019; 13(1): 15-30, CrossRef.
Gulizia MM, Maggioni AP, Abrignani MG, Bilato C, Mangiacapra F, Piovaccari G, et al. Prevalence of familial hypercholesterolaemia (FH) in Italian patients with coronary artery disease: The POSTER study. Atherosclerosis. 2020; 308: 32-8, CrossRef.
Corella D, Tai ES, Sorlí JV, Chew SK, Coltell O, Sotos-Prieto M, et al. Association between the APOA2 promoter polymorphism and body weight in Mediterranean and Asian populations: replication of a gene-saturated fat interaction. Int J Obes. 2010; 35(5): 666-75, CrossRef.
Guan W, Steffen LM, Rewers M, Loria CM, Chen YD. Dietary saturated fat and the 5-year change in high-density lipoprotein cholesterol concentration: The coronary artery risk development in young adults study. Am J Clin Nutr. 2010; 91(4): 951-8.
Domínguez-Reyes T, Astudillo-López CC, Salgado-Goytia L, Muñoz-Valle JF, Salgado-Bernabé AB, Guzmán-Guzmán IP, et al. Interaction of dietary fat intake with APOA2, APOA5 and LEPR polymorphisms and its relationship with obesity and dyslipidemia in young subjects. Lipids Health Dis. 2015; 14: 106, CrossRef.
Abaj F, Esmaeily Z, Naeini Z, Rafiee M, Koohdani F. Dietary acid load modifies the effects of ApoA2-265 T > C polymorphism on lipid profile and serum leptin and ghrelin levels among type 2 diabetic patients. BMC Endocr Disord. 2022; 22(1): 190, CrossRef.
Esmaeily Z, Sotoudeh G, Rafiee M, Koohdani F. ApoA2-256T> C polymorphism interacts with healthy eating index, dietary quality index-international and dietary phytochemical index to affect biochemical markers among type 2 diabetic patients. Br J Nutr. 2022; 127(9): 1343-51, CrossRef.
Kiani AK, Bonetti G, Donato K, Kaftalli J, Herbst KL, Stuppia L, et al. Polymorphisms, diet and nutrigenomics. J Prev Med Hyg. 2022; 63(2 Suppl 3): E125-E141, CrossRef.
DOI: https://doi.org/10.18585/inabj.v17i3.3472
Copyright (c) 2025 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
